Abstract
The ability to evade apoptosis is one of the defining hallmarks of cancer. It enables the survival of cancer cells under abnormal growth stimulation and mediates their increased resistance to treatment with cytotoxic drugs and radiation. Therefore, antiapoptotic proteins that counteract apoptosis signaling represent promising new therapeutic targets to impair cancer cell growth and enhance treatment response. As soon as RNA interference (RNAi) was demonstrated in mammalian cells, it rapidly became an essential tool for gene knockdown in preclinical models, making it possible to define the role of specific genes in the onset and progression of cancer and explore their potential as therapeutic targets. The present review summarizes the findings from studies relying on the use of RNAi-based approaches to functionally validate two members of the inhibitors of apoptosis protein family, survivin and Apollon/BRUCE, as new cancer therapeutic targets. Results collected thus far indicate that targeting the survivin network efficiently inhibits tumor growth potential and increases spontaneous and treatment-induced apoptosis of cancer cells. Based on these findings, the applicability of survivin-directed strategies for the clinical treatment of human tumors is currently under investigation. As regards Apollon/ BRUCE, although very preliminary, results of RNAi-mediated gene knockdown point to the possibility to significantly impair tumor cell proliferation through the induction of apoptosis.
Keywords: Apollon/BRUCE, apoptosis, chemosensitivity, human tumors, inhibitors of apoptosis proteins, radiosensitivity, survivin, cancer cells, therapeutic targets, clinical treatment of human tumors, mammalian cells, C-terminal Bid fragment (tBID), proapoptotic protein, controlled signaling pathways, inhibitors of apoptosis proteins (IAPs), human leukocyte
Current Topics in Medicinal Chemistry
Title: RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Volume: 12 Issue: 2
Author(s): Marzia Pennati, Enrico Millo, Paolo Gandellini, Marco Folini and Nadia Zaffaroni
Affiliation:
Keywords: Apollon/BRUCE, apoptosis, chemosensitivity, human tumors, inhibitors of apoptosis proteins, radiosensitivity, survivin, cancer cells, therapeutic targets, clinical treatment of human tumors, mammalian cells, C-terminal Bid fragment (tBID), proapoptotic protein, controlled signaling pathways, inhibitors of apoptosis proteins (IAPs), human leukocyte
Abstract: The ability to evade apoptosis is one of the defining hallmarks of cancer. It enables the survival of cancer cells under abnormal growth stimulation and mediates their increased resistance to treatment with cytotoxic drugs and radiation. Therefore, antiapoptotic proteins that counteract apoptosis signaling represent promising new therapeutic targets to impair cancer cell growth and enhance treatment response. As soon as RNA interference (RNAi) was demonstrated in mammalian cells, it rapidly became an essential tool for gene knockdown in preclinical models, making it possible to define the role of specific genes in the onset and progression of cancer and explore their potential as therapeutic targets. The present review summarizes the findings from studies relying on the use of RNAi-based approaches to functionally validate two members of the inhibitors of apoptosis protein family, survivin and Apollon/BRUCE, as new cancer therapeutic targets. Results collected thus far indicate that targeting the survivin network efficiently inhibits tumor growth potential and increases spontaneous and treatment-induced apoptosis of cancer cells. Based on these findings, the applicability of survivin-directed strategies for the clinical treatment of human tumors is currently under investigation. As regards Apollon/ BRUCE, although very preliminary, results of RNAi-mediated gene knockdown point to the possibility to significantly impair tumor cell proliferation through the induction of apoptosis.
Export Options
About this article
Cite this article as:
Pennati Marzia, Millo Enrico, Gandellini Paolo, Folini Marco and Zaffaroni Nadia, RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy, Current Topics in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/156802612798919169
DOI https://dx.doi.org/10.2174/156802612798919169 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy
Current Pharmaceutical Design Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity
Current Cancer Drug Targets Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Synthesis and Biological Evaluation of 1, 3-Dihydroxyxanthone Mannich Base Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery Novel Methods for the Non-Invasive Administration of DNA Therapeutics and Vaccines
Current Drug Delivery Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis
Current Respiratory Medicine Reviews Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines
Anti-Cancer Agents in Medicinal Chemistry Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice
Current Drug Metabolism